School of Medicine


Showing 1-50 of 58 Results

  • Kimberly Allison

    Kimberly Allison

    Professor of Pathology

    Current Research and Scholarly InterestsDr. Allison’s clinical expertise is in breast pathology. Her research interests include how standards should be applied to breast cancer diagnostics (such as ER and HER2 testing), the utility of molecular panel-based testing in breast cancer, digital pathology applications and identifying the most appropriate management of specific pathologic diagnoses.

  • Leah Backhus

    Leah Backhus

    Associate Professor of Cardiothoracic Surgery (Thoracic Surgery)

    BioLeah Backhus trained in general surgery at the University of Southern California and cardiothoracic surgery at the University of California Los Angeles. She practices at Stanford Hospital and is Chief of Thoracic Surgery at the VA Palo Alto. Her surgical practice consists of general thoracic surgery with special emphasis on thoracic oncology and minimally invasive surgical techniques. She is also Co-Director of the Thoracic Surgery Clinical Research Program, and has grant funding through the Veterans Affairs Administration and NIH. Her current research interests are in imaging surveillance following treatment for lung cancer and cancer survivorship. She is a member of the National Lung Cancer Roundtable of the American Cancer Society serving as Chair of the Task Group on Lung Cancer in Women. She also serves on the Board of Directors of the Society of Thoracic Surgeons. As an educator, Dr. Backhus is the Associate Program Director for the Thoracic Track Residency and is the Chair of the ACGME Residency Review Committee for Thoracic Surgery which is the accrediting body for all cardiothoracic surgery training programs in the US.

  • Michael Bassik

    Michael Bassik

    Associate Professor of Genetics

    Current Research and Scholarly InterestsWe are an interdisciplinary lab focused on two major areas:(1) we seek to understand mechanisms of cancer growth and drug resistance in order to find new therapeutic targets(2) we study mechanisms by which macrophages and other cells take up diverse materials by endocytosis and phagocytosis; these substrates range from bacteria, viruses, and cancer cells to drugs and protein toxins. To accomplish these goals, we develop and use new technologies for high-throughput functional genomics.

  • Carolyn Bertozzi

    Carolyn Bertozzi

    Baker Family Director of Stanford ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology

    BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.

    Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.

    Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.

    The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.

    Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.

  • Matthew Bogyo

    Matthew Bogyo

    Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsOur lab uses chemical, biochemical, and cell biological methods to study protease function in human disease. Projects include:

    1) Design and synthesis of novel chemical probes for serine and cysteine hydrolases.

    2) Understanding the role of hydrolases in bacterial pathogenesis and the human parasites, Plasmodium falciparum and Toxoplasma gondii.

    3) Defining the specific functional roles of proteases during the process of tumorogenesis.

    4) In vivo imaging of protease activity

  • Nam Quoc Bui

    Nam Quoc Bui

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in the Sarcoma and Developmental Therapeutics programs. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies.

  • Jennifer Caswell-Jin

    Jennifer Caswell-Jin

    Assistant Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsMy research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.

  • James K. Chen

    James K. Chen

    Jauch Professor and Professor of Chemical and Systems Biology, of Developmental Biology and of Chemistry

    Current Research and Scholarly InterestsOur laboratory combines chemistry and developmental biology to investigate the molecular events that regulate embryonic patterning, tissue regeneration, and tumorigenesis. We are currently using genetic and small-molecule approaches to study the molecular mechanisms of Hedgehog signaling, and we are developing chemical technologies to perturb and observe the genetic programs that underlie vertebrate development.

  • Bill Chiu

    Bill Chiu

    Associate Professor of Surgery (Pediatric Surgery)

    BioDr. Chiu obtained his B.S. degree in Biological Sciences and graduated with Honors from Stanford University. After graduating, he received his Medical Degree at Northwestern University Feinberg School of Medicine, where he remained for his internship and General Surgery residency training. Dr. Chiu completed his Pediatric Surgery training at The Children’s Hospital of Philadelphia. He is an Associate Professor at Stanford University School of Medicine where he has an active research program studying innovative approaches to treat patients with neuroblastoma.

  • Jennifer R. Cochran

    Jennifer R. Cochran

    Shriram Chair of the Department of Bioengineering, Professor of Bioengineering and, by courtesy, of Chemical Engineering

    Current Research and Scholarly InterestsMolecular Engineering, Protein Biochemistry, Biotechnology, Cell and Tissue Engineering, Molecular Imaging, Chemical Biology

  • A. Dimitrios Colevas

    A. Dimitrios Colevas

    Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

    Current Research and Scholarly InterestsMulti- modality treatment of Head and Neck Cancer

    Phase 1 clinical trials

  • Hongjie Dai

    Hongjie Dai

    The J.G. Jackson and C.J. Wood Professor of Chemistry

    BioProfessor Dai’s research spans chemistry, physics, and materials and biomedical sciences, leading to materials with properties useful in electronics, energy storage and biomedicine. Recent developments include near-infrared-II fluorescence imaging, ultra-sensitive diagnostic assays, a fast-charging aluminum battery and inexpensive electrocatalysts that split water into oxygen and hydrogen fuels.

    Born in 1966 in Shaoyang, China, Hongjie Dai began his formal studies in physics at Tsinghua U. (B.S. 1989) and applied sciences at Columbia U. (M.S. 1991). He obtained his Ph.D. from Harvard U and performed postdoctoral research with Dr. Richard Smalley. He joined the Stanford faculty in 1997, and in 2007 was named Jackson–Wood Professor of Chemistry. Among many awards, he has been recognized with the ACS Pure Chemistry Award, APS McGroddy Prize for New Materials, Julius Springer Prize for Applied Physics and Materials Research Society Mid-Career Award. He has been elected to the American Academy of Arts and Sciences, National Academy of Sciences (NAS), National Academy of Medicine (NAM) and Foreign Member of Chinese Academy of Sciences.

    The Dai Laboratory has advanced the synthesis and basic understanding of carbon nanomaterials and applications in nanoelectronics, nanomedicine, energy storage and electrocatalysis.

    Nanomaterials
    The Dai Lab pioneered some of the now-widespread uses of chemical vapor deposition for carbon nanotube (CNT) growth, including vertically aligned nanotubes and patterned growth of single-walled CNTs on wafer substrates, facilitating fundamental studies of their intrinsic properties. The group developed the synthesis of graphene nanoribbons, and of nanocrystals and nanoparticles on CNTs and graphene with controlled degrees of oxidation, producing a class of strongly coupled hybrid materials with advanced properties for electrochemistry, electrocatalysis and photocatalysis. The lab’s synthesis of a novel plasmonic gold film has enhanced near-infrared fluorescence up to 100-fold, enabling ultra-sensitive assays of disease biomarkers.

    Nanoscale Physics and Electronics
    High quality nanotubes from his group’s synthesis are widely used to investigate the electrical, mechanical, optical, electro-mechanical and thermal properties of quasi-one-dimensional systems. Lab members have studied ballistic electron transport in nanotubes and demonstrated nanotube-based nanosensors, Pd ohmic contacts and ballistic field effect transistors with integrated high-kappa dielectrics.

    Nanomedicine and NIR-II Imaging
    Advancing biological research with CNTs and nano-graphene, group members have developed π–π stacking non-covalent functionalization chemistry, molecular cellular delivery (drugs, proteins and siRNA), in vivo anti-cancer drug delivery and in vivo photothermal ablation of cancer. Using nanotubes as novel contrast agents, lab collaborations have developed in vitro and in vivo Raman, photoacoustic and fluorescence imaging. Lab members have exploited the physics of reduced light scattering in the near-infrared-II (1000-1700nm) window and pioneered NIR-II fluorescence imaging to increase tissue penetration depth in vivo. Video-rate NIR-II imaging can measure blood flow in single vessels in real time. The lab has developed novel NIR-II fluorescence agents, including CNTs, quantum dots, conjugated polymers and small organic dyes with promise for clinical translation.

    Electrocatalysis and Batteries
    The Dai group’s nanocarbon–inorganic particle hybrid materials have opened new directions in energy research. Advances include electrocatalysts for oxygen reduction and water splitting catalysts including NiFe layered-double-hydroxide for oxygen evolution. Recently, the group also demonstrated an aluminum ion battery with graphite cathodes and ionic liquid electrolytes, a substantial breakthrough in battery science.

  • Millie Das

    Millie Das

    Clinical Associate Professor, Medicine - Oncology

    BioDr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.

  • Kaniksha Desai

    Kaniksha Desai

    Clinical Assistant Professor, Medicine - Endocrinology, Gerontology, & Metabolism

    BioDr. Kaniksha Desai is a board-certified endocrinologist and clinical assistant professor of endocrinology at Stanford University. She completed her endocrinology fellowship at the Mayo Clinic, with an emphasis on the management of patients with thyroid cancer. Dr. Desai’s clinical practice focuses on the management of patients with thyroid diseases, including thyroid nodules and thyroid cancers, and the management of patients with pituitary disorders. She also maintains board certification in neck ultrasonography and internal medicine.

  • Joseph M. DeSimone

    Joseph M. DeSimone

    Sanjiv Sam Gambhir Professor of Translational Medicine, Professor of Chemical Engineering and, by courtesy, of Chemistry, of Materials Science and Engineering, and of Operations, Information and Technology at the Graduate School of Business

    BioJoseph M. DeSimone is the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He holds appointments in the Departments of Radiology and Chemical Engineering with courtesy appointments in the Department of Chemistry and in Stanford’s Graduate School of Business.

    The DeSimone laboratory's research efforts are focused on developing innovative, interdisciplinary solutions to complex problems centered around advanced polymer 3D fabrication methods. In Chemical Engineering and Materials Science, the lab is pursuing new capabilities in digital 3D printing, as well as the synthesis of new polymers for use in advanced additive technologies. In Translational Medicine, research is focused on exploiting 3D digital fabrication tools to engineer new vaccine platforms, enhanced drug delivery approaches, and improved medical devices for numerous conditions, with a current major focus in pediatrics. Complementing these research areas, the DeSimone group has a third focus in Entrepreneurship, Digital Transformation, and Manufacturing.

    Before joining Stanford in 2020, DeSimone was a professor of chemistry at the University of North Carolina at Chapel Hill and of chemical engineering at North Carolina State University. He is also Co-founder, Board Chair, and former CEO (2014 - 2019) of the additive manufacturing company, Carbon. DeSimone is responsible for numerous breakthroughs in his career in areas including green chemistry, medical devices, nanomedicine, and 3D printing. He has published over 350 scientific articles and is a named inventor on over 200 issued patents. Additionally, he has mentored 80 students through Ph.D. completion in his career, half of whom are women and members of underrepresented groups in STEM.

    In 2016 DeSimone was recognized by President Barack Obama with the National Medal of Technology and Innovation, the highest U.S. honor for achievement and leadership in advancing technological progress. He has received numerous other major awards in his career, including the U.S. Presidential Green Chemistry Challenge Award (1997); the American Chemical Society Award for Creative Invention (2005); the Lemelson-MIT Prize (2008); the NIH Director’s Pioneer Award (2009); the AAAS Mentor Award (2010); the Heinz Award for Technology, the Economy and Employment (2017); the Wilhelm Exner Medal (2019); the EY Entrepreneur of the Year Award (2019 U.S. Overall National Winner); and the Harvey Prize in Science and Technology (2020). He is one of only 25 individuals elected to all three branches of the U.S. National Academies (Sciences, Medicine, Engineering). DeSimone received his B.S. in Chemistry in 1986 from Ursinus College and his Ph.D. in Chemistry in 1990 from Virginia Tech.

  • Frederick M. Dirbas, MD

    Frederick M. Dirbas, MD

    Associate Professor of Surgery (General Surgery)

    Current Research and Scholarly InterestsMy research interests are focused on minimizing the impact of breast cancer from a diagnostic and therapuetic standpoint. Breast MRI is a powerful tool to facilitate the screening for and staging of breast cancer, and can be valuable adjunct to guide breast surgery. Oncoplastic surgical techniques optimize cosmesis after breast cancer surgery. Accelerated radiotherapy after lumpectomy decreases radiotherapy treatment times from 6 weeks to just 1 to 5 days.

  • Alice C. Fan

    Alice C. Fan

    Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology

    Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.

  • Dean W. Felsher

    Dean W. Felsher

    Professor of Medicine (Oncology) and of Pathology

    Current Research and Scholarly InterestsMy laboratory investigates how oncogenes initiate and sustain tumorigenesis. I have developed model systems whereby I can conditionally activate oncogenes in normal human and mouse cells in tissue culture or in specific tissues of transgenic mice. In particular using the tetracycline regulatory system, I have generated a conditional model system for MYC-induced tumors. I have shown that cancers caused by the conditional over-expression of the MYC proto-oncogene regress with its inactivation.

  • George A. Fisher Jr.

    George A. Fisher Jr.

    Colleen Haas Chair in the School of Medicine

    Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.

  • James Ford

    James Ford

    Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics

    Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.

  • Kristen N Ganjoo

    Kristen N Ganjoo

    Associate Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsGiant cell tumor of the bone
    Gastrointestinal stromal tumors
    Soft tissue sarcoma
    Osteosarcoma

  • Gerald Grant, MD, FACS

    Gerald Grant, MD, FACS

    Botha Chan Endowed Professor and Professor, by courtesy, of Neurology

    Current Research and Scholarly InterestsDr. Grant directs a Blood-brain Barrier Translational Laboratory focusing on enhancing drug delivery to brain tumors in children.

  • Sigurdis Haraldsdottir

    Sigurdis Haraldsdottir

    BioDr. Sigurdis Haraldsdottir, M.D., Ph.D. is an Assistant Professor of Medicine at Stanford University School of Medicine. She received her medical degree and master's degree in medical sciences from the University of Iceland. She did her Internal Medicine training at Boston University Medical Center and training in Medical Oncology at the Ohio State University, before joining the faculty at Stanford. Her clinical and research focus is in gastrointestinal malignancies with a focus on mismatch repair deficient cancers, particularly colorectal cancer. She is conducting population-based research on Lynch syndrome - an inherited cancer syndrome, and recently completed a nation-wide study on Lynch syndrome in Iceland. She received her Ph.D. in Medical Sciences in 2017 from the University of Iceland. Her interests also focus on investigating colorectal cancer genomics, and their effect on outcomes and treatment implications.

  • Pehr Harbury

    Pehr Harbury

    Associate Professor of Biochemistry

    Current Research and Scholarly InterestsScientific breakthroughs often come on the heels of technological advances; advances that expose hidden truths of nature, and provide tools for engineering the world around us. Examples include the telescope (heliocentrism), the Michelson interferometer (relativity) and recombinant DNA (molecular evolution). Our lab explores innovative experimental approaches to problems in molecular biochemistry, focusing on technologies with the potential for broad impact.

  • Melanie Hayden Gephart

    Melanie Hayden Gephart

    Associate Professor of Neurosurgery and, by courtesy, of Neurology

    BioI am a brain tumor neurosurgeon, treating patients with malignant and benign tumors, including glioma, brain metastases, meningioma, vestibular schwannoma, and pituitary adenomas. Our lab seeks greater understanding of the genetic and epigenetic mechanisms driving tumorigenesis and disease progression in malignant brain tumors. We currently study the capacity of cellular and cell-free nucleic acids to inform cancer biology and response to therapy. We also use single cell and cell subtype-specific transcriptomics to identify and target malignant cancer cells, mechanisms of tumor migration, and to stop tumor growth. Our laboratory is a unique and collaborative working environment, engaged in a dynamic research environment at Stanford. Our laboratory space lies at the heart of the Stanford campus between the core campus and the medical facilities, emblematic of the translational aspects of our work.

    www.GephartLab.com
    www.GBMseq.org
    https://stan.md/BrainMets
    @HaydenGephartMD

  • Chris Holsinger

    Chris Holsinger

    Professor of Otolaryngology - Head & Neck Surgery (OHNS)

    Current Research and Scholarly InterestsDr. Holsinger’s surgical practice focuses on the surgical management of benign and malignant diseases of the thyroid, parathyroid and head and neck.

    His areas of clinical interest include endoscopic head and neck surgery, including robotic thyroidectomy, transoral robotic surgery and transoral laser microsurgery, as well as time-honoured approaches of conservation laryngeal surgery, supracricoid partial laryngectomy.

  • Stefanie S. Jeffrey, MD

    Stefanie S. Jeffrey, MD

    John and Marva Warnock Professor, Emerita

    Current Research and Scholarly InterestsDr. Jeffrey led the multidisciplinary team from the Schools of Medicine, Engineering, and Genome Technology Center that invented the MagSweeper, an automated device that immunomagnetically captures live circulating tumor cells (CTCs) from cancer patient blood for single cell analysis or culture. Her lab also works on microfluidic technologies for tumor cell capture, characterization, and growth - with the goal of defining individual patient response to newer biologically-based cancer therapies.

  • Mark A. Kay, M.D., Ph.D.

    Mark A. Kay, M.D., Ph.D.

    Dennis Farrey Family Professor of Pediatrics, and Professor of Genetics

    Current Research and Scholarly InterestsMark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.

  • Electron Kebebew, MD, FACS

    Electron Kebebew, MD, FACS

    Harry A. Oberhelman, Jr. and Mark L. Welton Professor

    Current Research and Scholarly InterestsDr. Kebebew’s translational and clinical investigations have three main scientific goals: 1) to develop effective therapies for fatal, rare and neglected endocrine cancers, 2) to identify new methods, strategies and technologies for improving the diagnosis and treatment of endocrine neoplasms and the prognostication of endocrine cancers, and 3) to develop methods for precision treatment of endocrine tumors.

  • Saad A. Khan, MD

    Saad A. Khan, MD

    Assistant Professor of Medicine (Oncology)

    BioSaad A. Khan, MD is a medical oncologist focused on the treatment of head and neck, thyroid and lung cancers. His research interests include therapeutic clinical trials as well as mechanisms of reducing toxicities that patients experience. His research activities include ongoing clinical trials of targeted and immune therapy in aggressive thyroid malignancies. He is a member of the NRG Head and Neck Committee, the ECOG Head and Neck Core and Thoracic Committees and the National Cancer Institute’s Head and Neck Steering Committee Rare Tumor Task Force.

    When not in clinic or the hospital he enjoys spending time with his family and 3 children, hiking and sitting on the beach.

  • Chaitan Khosla

    Chaitan Khosla

    Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry

    Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.

    For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.

    For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine.

  • Eric Kool

    Eric Kool

    George A. and Hilda M. Daubert Professor of Chemistry

    Current Research and Scholarly Interests• Design of cell-permeable reagents for profiling, modifying, and controlling RNAs
    • Developing fluorescent probes of DNA repair pathways, with applications in cancer, aging, and neurodegenerative disease
    • Discovery and development of small-molecule modulators of DNA repair enzymes, with focus on cancer and inflammation

  • Philip W. Lavori

    Philip W. Lavori

    Professor of Biomedical Data Science, Emeritus

    Current Research and Scholarly InterestsBiostatistics, clinical trials, longitudinal studies, casual inference from observational studies, genetic tissue banking, informed consent. Trial designs for dynamic (adaptive) treatment regimes, psychiatric research, cancer.

  • Shoshana Levy

    Shoshana Levy

    Professor (Research) of Medicine (Oncology)

    Current Research and Scholarly InterestsOur research focuses on the mechanism of action of tetraspanins, an evolutionary conserved, widely expressed multi-gene family. We study a prototype, CD81, a molecule implicated in the pathogenesis of two major human diseases: hepatitis C virus (HCV) and malaria.

  • AC Matin

    AC Matin

    Professor of Microbiology and Immunology, Emeritus

    Current Research and Scholarly Interests1. Improvement of our newly discovered cancer prodrug regimen that permits noninvaisve visualization of drug activation. 2. Tracking tumors & cancer metastases using bacterial magnetite and newly developed single-cell tracking by MRI. 3. Molecular basis of bacterial planktonic and biofilm antibiotic resistance on Earth and under space microgravity -- development of new countermeasures; 4. Bioremediation.

  • Daria Mochly-Rosen

    Daria Mochly-Rosen

    George D. Smith Professor of Translational Medicine

    Current Research and Scholarly InterestsTwo areas: 1. Using rationally-designed peptide inhibitors to study protein-protein interactions in cell signaling. Focus: protein kinase C in heart and large GTPases regulating mitochondrial dynamics in neurodegdenration. 2. Using small molecules (identified in a high throughput screens and synthetic chemistry) as activators and inhibitors of aldehyde dehydrogenases, a family of detoxifying enzymes, and glucose-6-phoshate dehydrogenase, in normal cells and in models of human diseases.

  • Michelle Monje

    Michelle Monje

    Associate Professor of Neurology and, by courtesy, of Neurosurgery, of Pediatrics, of Pathology and of Psychiatry and Behavioral Sciences

    Current Research and Scholarly InterestsThe Monje Lab studies the molecular and cellular mechanisms of postnatal neurodevelopment. This includes microenvironmental influences on neural precursor cell fate choice in normal neurodevelopment and in disease states.

  • Prithvi Mruthyunjaya, MD, MHS

    Prithvi Mruthyunjaya, MD, MHS

    Associate Professor of Ophthalmology

    Current Research and Scholarly InterestsDr Mruthyunjaya has maintained a broad research interest with publications in both ocular oncology and retinal diseases.
    His focus is on multi-modal imaging of ocular tumors and understanding imaging clues that may predict vision loss after ocular radiation therapy. He coordinates multi-center research on the role of genetic testing and outcomes of treatments of ocular melanoma.
    In the field of retinal diseases, his interests are in intra-operative imaging to enhance surgical accuracy.

  • Joel Neal, MD, PhD

    Joel Neal, MD, PhD

    Associate Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsI am a thoracic oncologist who cares for patients with non-small cell lung cancer, malignant mesothelioma, and other thoracic malignancies. I design and conduct clinical trials of novel therapies in collaboration with other researchers and pharmaceutical companies. These generally focus on two areas, 1) targeted therapies against particular mutations in cancers (for example EGFR, ALK, ROS1, HER2, KRAS, MET, and others) and 2) the emerging field of immunotherapy in cancer, using anti PD-1/PD-L1 therapies in combination with other agents, and also developing cellular therapies. I also collaborate with other researchers on campus to apply emerging technologies to cancer therapy, for example, circulating tumor DNA detection. Additionally, in my role as the Cancer Center IT Medical Director, I coordinate projects relating to our use of the electronic health record to improve provider efficiency and facilitate patient care.

  • Mark Pegram

    Mark Pegram

    Susy Yuan-Huey Hung Professor

    Current Research and Scholarly InterestsMolecular mechanisms of targeted therapy resistance in breast and other cancers

  • Lawrence Recht, MD

    Lawrence Recht, MD

    Professor of Neurology and, by courtesy, of Neurosurgery

    Current Research and Scholarly InterestsOur laboratory focuses on two interrelated projects: (1) assessment of glioma development within the framework of the multistage model of carcinogenesis through utilization of the rodent model of ENU neurocarcinogenesis; and (2) assessment of stem cell specification and pluripotency using an embryonic stem cell model system in which neural differentiation is induced.

  • Stanley G. Rockson, MD

    Stanley G. Rockson, MD

    Allan and Tina Neill Professor of Lymphatic Research and Medicine

    Current Research and Scholarly InterestsMy clinical research includes studies on risk factor modification in atherosclerosis and coronary artery disease; clinical trials involving medical therapies for peripheral arterial insufficiency; coronary angiogenesis; therapy of lymphedema; atherand photodynamic therapy in atherosclerosis.

  • Eben Rosenthal

    Eben Rosenthal

    Professor of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiology (Molecular Imaging Program at Stanford)

    BioEben Rosenthal is a surgeon-scientist and academic leader. He is currently serving as the John and Ann Doerr Medical Director of the Stanford Cancer Center, a position he has held since July 2015. He works collaboratively with the Stanford Cancer Institute and Stanford Health Care leaders to set the strategy for the clinical delivery of cancer care across Stanford Medicine and growing cancer networks.

    Before coming to Stanford, he learned his surgical skills in otolaryngology from the University of Michigan and traveled west for further training in facial plastic and reconstructive surgery at the Oregon Health and Science University. He joined the faculty at University of Alabama at Birmingham where he started as an Assistant Professor of Surgery within the Division of Otolaryngology. In 2012, Dr. Rosenthal became Division Director of Otolaryngology – Head and Neck Surgery and the holder of the John S. Odess Endowed Chair at the University of Alabama at Birmingham. He moved to Stanford in 2015 to become the Ann and John Doerr Medical Director of the Stanford Cancer Center.

    Dr. Rosenthal is certified by the American Board of Otolaryngology and is a Diplomat of the American Board of Facial Plastic and Reconstructive Surgery. He specializes in the treatment and reconstruction of head and neck cancer patients. He has a strong interest in development of new strategies to surgically repair complex head and neck defects to improve functional and cosmetic outcomes.

    He has published over 160 peer-reviewed scientific manuscripts, authored many book chapters and published a book on optical imaging in cancer. He is on the editorial board of Head & Neck and The Laryngoscope and is also a charter member of the NIH Developmental Therapeutics Study Section. Dr. Rosenthal has performed preclinical and clinical research on the role of targeted therapies for use to treat cancer alone and in combination with conventional therapy. He has served as principal investigator on several early phase investigator-initiated and industry sponsored clinical trials in molecular oncology. He has received grant funding from the American Cancer Society, NIH/NCI and NIH/NIDCR to study the role of targeted therapy and novel imaging strategies in cancer.

    Dr. Rosenthal has conducted bench to bedside development of optical contrast agents to identify cancer in the operating room. He led a multidisciplinary team of scientists through successful IND application to allow testing of fluorescently labeled antibodies in the clinic and operating room. These early phase clinical trials have demonstrated that this technique can visualize microscopic cancer in the operating room and may significantly improve clinical outcomes.

  • Joseph Shrager

    Joseph Shrager

    Professor of Cardiothoracic Surgery

    Current Research and Scholarly InterestsIn clinical research, Dr. Shrager has been an innovator studying outcomes in a variety of areas within Thoracic Surgery including: parenchyma-sparing operations and minimally invasive resections for lung cancer, transcervical thymectomy for myasthenia gravis, and surgical treatment of emphysema.

    In the lab, Dr. Shrager is focused on the impact of disease states upon the diaphragm. His group published the seminal paper (NEJM) describing diaphragm atrophy assoc'd with mechanical ventilation.

  • Branimir I. Sikic, M. D.

    Branimir I. Sikic, M. D.

    Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers

  • Eila C. Skinner

    Eila C. Skinner

    Thomas A. Stamey Research Professor of Urology

    Current Research and Scholarly InterestsMy research focuses on outcomes in the treatment of muscle invasive and high-grade non-muscle invasive bladder cancer. This includes identifying markers of prognosis, predictive markers for response to surgery and chemotherapy, and working toward an individualized, multidisciplinary approach to disease management. I have also focused on optimizing the use of lower urinary tract reconstruction in patients undergoing cystectomy, and developing interventions to improve patient quality of life.

  • Sheri Spunt

    Sheri Spunt

    Endowed Professor of Pediatric Cancer

    Current Research and Scholarly InterestsMy research focuses primarily on the management of children, adolescents, and young adults with soft tissue sarcomas. I also have an interest in developmental therapeutics and late effects of cancer therapy,

  • Sandy Srinivas

    Sandy Srinivas

    Professor of Medicine (Oncology) and, by courtesy, of Urology

    Current Research and Scholarly InterestsClinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma

  • Tanya Stoyanova

    Tanya Stoyanova

    Assistant Professor of Radiology (Cancer Early Detection-Canary Center)

    Current Research and Scholarly InterestsStoyanova lab develops new early cancer detection methods and therapeutic strategies for late stage cancers. The current research focus is on protein-based biomarkers for early cancer detection as well as development of new small molecule inhibitors and antibody-based therapies for prostate and other epithelial cancers. The ultimate goals of the laboratory are to improve the early diagnosis and prognosis of clinically significant cancers and guide the development of novel and effective therapeutic strategies for metastatic prostate and other epithelial cancers.